KLK2 and neoplasm: Herein we report a technology platformbased on novel activity-based probes (ABPs) and inhibitors enablingsimultaneous orthogonal analysis of KLK2, KLK3, and KLK14 activityin hormone-responsive PCa cell lines and tumor homogenates.